• Vaccine Name: Bovine herpesvirus 1 DNA vaccine tgD-VP22
• Target Pathogen: Bovine herpesvirus 1
• Target Disease: Infectious bovine rhinotracheitis
• Vaccine Ontology ID: VO_0011554
• Type: DNA vaccine
• Status: Research
• Antigen: Bovine herpesvirus 1 tegument protein VP22 and glycoprotein D
• UL49 gene engineering:
  • Type: DNA vaccine construction
  • Description: Researchers constructed the plasmids pVP22-YFP, pMASIA-tgD-YFP, and pMASIA-tgD-VP22-YFP. For the construction of pVP22-YFP, the UL49 (VP22 gene) open reading frame was amplified from BHV-1 genomic DNA by PCR and then inserted into pEYFP-N1 (Clontech, BD Biosciences, Palo Alto, Calif.). Subsequently, pMASIA-tgD-YFP and pMASIA-tgD-VP22-YFP were generated by PCR cloning of the YFP and VP22-YFP genes from pEYFP-N1 and pVP22-YFP, respectively, into pMASIA-tgD, which encodes BHV-1 tgD (26). COS-7 cells were transfected with pMASIA-tgD-VP22-YFP, pMASIA-tgD-YFP, and pVP22-YFP and monitored every 4 h by fluorescence microscopy (Zheng et al., 2005).
  • Detailed Gene Information: Click Here.
• US6 gene engineering:
  • Type: DNA vaccine construction
  • Description: Researchers constructed the plasmids pVP22-YFP, pMASIA-tgD-YFP, and pMASIA-tgD-VP22-YFP. For the construction of pVP22-YFP, the UL49 (VP22 gene) open reading frame was amplified from BHV-1 genomic DNA by PCR and then inserted into pEYFP-N1 (Clontech, BD Biosciences, Palo Alto, Calif.). Subsequently, pMASIA-tgD-YFP and pMASIA-tgD-VP22-YFP were generated by PCR cloning of the YFP and VP22-YFP genes from pEYFP-N1 and pVP22-YFP, respectively, into pMASIA-tgD, which encodes BHV-1 tgD (26). COS-7 cells were transfected with pMASIA-tgD-VP22-YFP, pMASIA-tgD-YFP, and pVP22-YFP and monitored every 4 h by fluorescence microscopy (Zheng et al., 2005).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0005026
• Immunization Route: Intradermal injection (i.d.)

Cattle Response

• Vaccination Protocol: Calves were immunized intradermally with 500 μg of pMASIA-tgD-VP22, 500 μg of pMASIA-tgD, or saline in a 500-μl volume by use of the Biojector 2000 needle-free injection system (Bioject, Bedminster, N.J.) (Zheng et al., 2005).
• Challenge Protocol: All animals were reimmunized after 28 days and were challenged with BHV-1 strain 108 on day 54. All data from this study were analyzed with the aid of Graphpad Prism 3.0 (Zheng et al., 2005).
• Efficacy: Protection against a BHV-1 challenge was obtained in calves immunized with the plasmid encoding tgD-VP22 (UL49), as shown by significant reductions in viral excretion (Zheng et al., 2005).